Accreditation Expired
Guideline approaches to type 2 diabetes: How much has changed?
GlobalAn overview of international guidelines for type 2 diabetes presented at EASD 2022
Guideline approaches to type 2 diabetes: How much has changed?
Since the emergence of data from cardiovascular outcome trials (CVOTs) revealing cardioprotective effects of some antihyperglycaemic agents, there has been a period of significant change in guideline recommendations for managing type 2 diabetes.
Presented during a satellite symposium at EASD 2022, in this video Prof. Tina Vilsbøll presents an overview of international guidelines for type 2 diabetes and how they have evolved in recent years.
Pre-Activity Information
This educational activity is intended for an international audience of non-US and non-UK diabetologists and endocrinologists
Upon completion of this activity, participants will be able to:
- Recall the cardiovascular benefits associated with the GLP-1 RA class, and relevant guideline recommendations relating to these
Faculty: Professor Tina Vilsbøll
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Consultant | AstraZeneca, BMS, Eli Lilly, Mundipharma, Novo Nordisk, Sanofi |
| Speaker | AstraZeneca, BMS, Eli Lilly, Mundipharma, Novo Nordisk, Sanofi |
| Grant | Eli Lilly |
Staff Disclosures
Liberum IME staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This symposium has been funded by an arms-length educational grant from Novo Nordisk A/S. The content has been developed by the faculty in collaboration with Liberum IME. Novo Nordisk A/S has had no influence on the content or faculty selection.
This module was published on the 25th October 2022.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.